Daunorubicin Hydrochloride and Cytarabine Liposome
Daunorubicin Hydrochloride and Cytarabine Liposome · Cytotoxic Antimetabolite Chemotherapeutic Agent
Indications & Uses
Colorectal, Pancreatic, Breast, Non-Small Cell Lung Cancer, Myelodysplastic Syndromes (MDS), and Acute/Chronic Leukemias.
Contraindications
Hypersensitivity to active ingredient or any formulation excipients.
Side Effects & Warnings
Myelosuppression, mucositis, diarrhea, hand-foot syndrome, nausea, transaminitis, alopecia.
Drug & Dietary Interactions
Caution with strong CYP3A inhibitors or inducers; review concurrent medications.
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Patient & Caregiver Support
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.
